ASH 2022 | Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, describes the results of a comparative analysis of lisocabtagene maraleucel (liso-cel) in the Phase II PILOT study (NCT03483103) versus conventional chemotherapy regimens in the real-world in patients with relapsed/refractory (R/R) Large B-Cell Lymphoma (LBCL) for whom transplant was not intended. Overall, the study showed improved efficacy outcomes, including event-free survival (EFS), progression-free survival (PFS), and median duration of response for patients treated with liso-cel, supporting the use of this CAR-T therapy as a second-line treatment for R/R LBCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy; Loxo Oncology: Consultancy; Novartis: Consultancy; Roche/Genentech: Consultancy, Research Funding; Karyopharm: Consultancy; Incyte: Consultancy; Beigene: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Pharmacyclics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; TG Therapeautics: Consultancy, Research Funding; Seagen: Consultancy; Levine Cancer Institute: Current Employment, Honoraria, Research Funding; Adaptive Biotech: Consultancy; ADC Therapeautics: Consultancy; Epizyme: Speakers Bureau; Morphosys: Research Funding; AbbVie: Research Funding.
